Expression of metastasis-associated molecules in non-small cell lung cancer and their prognostic significance

Molecular Medicine Reports

Volumn 3, Issue 1, 2010, Pages 43-49

  Beom, Jin Lim ^a,b   Sung, Soo Jung ^a   Song, Yi Choi ^a   Choong, Sik Lee ^a  

^a Chungnam National University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Carcinoma; Cyclooxygenase 2; Matrix metalloproteinases; Non small cell lung; Survival analysis

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

EID: 76149142776     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000216     Document Type: Article

References (41)

1. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.
2. Parkin M, Samet J, Tyczynski JE, Shields P, Boffetta P and Caporaso N: Lung cancer epidemiology and etiology. In: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Travis WD, Brambilla E, Müller- Hermelink HK and Harris CC (eds). IARC Press, Lyon, pp12-15, 2004.
3. Alam N, Darling G, Shepherd FA, Mackay JA and Evans WK: Postoperative chemotherapy in nonsmall cell lung cancer: a systematic review. Ann Thorac Surg 81: 1926-1936, 2006.
4. Deslauriers J: Current surgical treatment of non-small cell lung cancer 2001. Eur Respir J Suppl 35: 61-70, 2002.
5. Zhu CQ, Shih W, Ling CH and Tsao MS: Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J clin Pathol 59: 790-800, 2006.
6. Gueders MM, Foidart JM, Noel A and Cataldo DD: Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. Eur J Pharmacol 533: 133-144, 2006.
7. Xu J, Benyon RC, Leir SH, Zhang S, Holgate ST and Lackie PM: Matrix metalloproteinase-2 from bronchial epithelial cells induces the proliferation of subepithelial fibroblasts. Clin Exp Allergy 32: 881-888, 2002.
8. Hida T Yatabe Y, Achiwa H, et al: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58: 3761-3764, 1998.
9. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H and Ristimaki A: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58: 4997-5001, 1998.
10. Tsujii M and DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501, 1995.
11. Chan TA, Morin PJ, Vogelstein B and Kinzler KW: Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95: 681-686, 1998.
12. Stolina M, Sharma S, Lin Y, et al: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164: 361-370, 2000.
13. Mascaux C, Martin B, Paesmans M, et al: Has Cox-2 a prognostic role in non-small cell lung cancer? A systematic review of the literature with meta-analysis of the survival results. Br J Cancer 95: 139-145, 2006.
14. Bremnes RM, Veve R, Hirsch FR and Franklin WA: The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis and prognosis. Lung Cancer 36: 115-124, 2002.
15. Hajra KM and Fearon ER: Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 34: 255-268, 2002.
16. Mino N, Takenaka K, Sonobe M, et al: Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer. J Surg Oncol 95: 250-257, 2007.
17. Thomas P, Khokha R, Shepherd FA, Feld R and Tsao MS: Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol 190: 150-156, 2000.
18. McCawley LJ, Crawford HC, King LE Jr, Mudgett J and Matrisian LM: A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res 64: 6965-6972, 2004.
19. Sienel W, Hellers J, Morresi-Hauf A, et al: Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 103: 647-651, 2003.
20. Cox G, Jones JL and O'Byrne KJ: Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. clin Cancer Res 6: 2349-2355, 2000.
21. Yamaguchi NH, Lichtenfels AJ, Demarchi LM, et al: COX-2, MMP-9 and Noguchi classification provide additional prognostic information about adenocarcinoma of the lung. A study of 117 patients from Brazil. Am J Clin Pathol 121: 78-86, 2004.
22. Martins SJ, Takagaki TV, Silva AG, Gallo CP, Silva FB and Capelozzi VL: Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma. Lung Cancer 64: 105-109, 2009.
23. Gouyer V, Conti M, Devos P, et al: Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Cancer 103: 1676-1684, 2005.
24. Simi L, Andreani M, Davini F, Janni A, Pazzagli M, Serio M and Orlando C: Simultaneous measurement of MMP9 and TIMP1 mRNA in human non-small cell lung cancers by multiplex real time RT-PCR. Lung Cancer 45: 171-179, 2004.
25. Suemitsu R, Yoshino I, Tomiyasu M, Fukuyama S, Okamoto T and Machan Y: Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer. Surg Today 34: 896-901, 2004.
26. Bertaux B, Hornebeek W, Eisen AZ and Dubertret L: Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol 97: 679-685, 1991.
27. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E and Iwata K: Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298: 29-32, 1992.
28. Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A and Stetler-Stevenson M: In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 102: 2002-2010, 1998.
29. Li G, Fridman R and Kim HR: Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 59: 6267-6275, 1999.
30. Murray GI, Duncan ME, O'Neil P, Melvin WTand Fothesgill JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 2: 461-462, 1996.
31. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT and Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 185: 256-261, 1998.
32. Nakopoulou L, Giannopoulou I, Gakiopoulou H, Liapis H, Tzonou A and Davaris PS: Matrix metalloprotcinase-1 and -3 in breast cancer: correlation with progesterone receptors and other clinicopathologic features. Hum Pathol 30: 436-442, 1999.
33. Fang S, Jin X, Wang R, et al: Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis 26: 481-486, 2005.
34. Zhu Y, Spitz MR, Lei L, Mills GB and Wu X: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 61: 7825-7829, 2001.
35. Su L, Zhou W, Park S, Wain JC, Lynch TJ, Liu G and Christiani DC: Matrix metalloproteinase-1 promoter polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 14: 567-570, 2005.
36. Sauter W, Rosenbesger A, Beckmann L, et al: Matrix metalloproteinase 1 (MMP1) is associated with early-onset lung cancer. Cancer Epidemiol Biomarkers Prey 17: 1127-1135, 2008.
37. Achiwa H, Yatabe Y, Hida T, et al: Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 5: 1001-1005, 1999.
38. Khuri FR, Wu H, Lee JJ, et al: Cyclooxygenase-2 overexpression is a marker of poorprognosis in stage I non-small cell lung cancer. Gin Cancer Res 7: 861-867, 2001.
39. Brabender J, Park J, Metzger R, et al: Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg 235: 440-443, 2002.
40. Hosomi Y, Yokose T, Hirose Y, Nakajima R, Nagai K, Nishiwaki Y and Ochiai A: Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 30: 73-81, 2000.
41. Marrogi Al, Travis WD, Welsh JA, et al: Nitric oxide synthase, cyclooxygenase 2 and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 6: 4739-4744, 2000.